Gritstone Bio

Home - Nexoplex Bio

United States · $92.7M raised

Business Model
B2B
Total Funding
$92.7M
Last Round
$92.7M Series BSep 2017
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Gritstone Bio, now operating as Nexoplex Bio after emerging from Chapter 11, develops next-generation cancer immunotherapies. The company focuses on multi-specific and bispecific antibodies that bind tumor targets and on generating potent, durable immune responses by targeting select antigens, including tumor-specific peptide–HLA complexes. Its scientific approach aims to help the immune system recognize and destroy diseased cells and to advance treatments for unmet needs in oncology.

Summary

Gritstone Bio is a Biotech company based in United States. It has raised $92.7M in total across 1 round, most recently a $92.7M Series B round in Sep 2017.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BSep 2017
$92.7M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gritstone Bio on Indexed.vc
<a href="https://indexed.vc/companies/gritstone-bio"><img src="https://indexed.vc/api/badge/company/gritstone-bio" alt="Gritstone Bio on Indexed.vc" width="260" height="76" /></a>